Visit Event Now
 

Learning Objectives:

Upon completion of this session, participants should be able to:

• Understand the safety and efficacy of OFEV for its latest indication
• Identify appropriate patients for treatment with OFEV
• Recognize the importance of having a multidisciplinary discussion when treating patients with OFEV

Needs Assessment:

The purpose of this symposium is to provide an overview of the OFEV pivotal safety and efficacy data and provide case study examples to underscore the importance of identifying appropriate patients for treatment with OFEV. This presentation is made on behalf of Boehringer Ingelheim Pharmaceuticals, Inc.

Presenters:

Cedric Jamie Rutland, MD
Rutland Medical Group
CEO and Medical Director
Riverside, California

UCR School of Medicine
Internal Medicine
Assistant Clinical Professor
Riverside, California

Francesco Boin, MD
Cedars-Sinai Medical Center
Division of Rheumatology
Director
Los Angeles, California

Credentials: Professor of Medicine Director, Division of Rheumatology Director, Scleroderma Center Kao Autoimmune Institute Cedars-Sinai Medical Center

This is not an official function/event of the American College of Rheumatology.